AltruBio

About:

AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases.

Website: https://www.altrubio.com

Top Investors: RA Capital Management, Cormorant Asset Management, Biotechnology Value Fund, Soleus Capital, aMoon Fund

Description:

AltruBio is focused on developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. AltruBio International in Delaware with principal office in SFO Bay Area California is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for unmet medical needs. Their R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages.

Total Funding Amount:

$328M

Headquarters Location:

Los Altos, California, United States

Founded Date:

2000-06-01

Contact Email:

abg(AT)abgenomics.com

Founders:

Rong-Hwa Lin

Number of Employees:

11-50

Last Funding Date:

2024-05-21

IPO Status:

Private

© 2025 bioDAO.ai